Cargando…

Financial Toxicity as an End Point in Prospective Clinical Trials Involving Radiation Therapy

Prior research, predominately retrospective, has increased awareness that patients with cancer are at elevated risk for financial toxicity (FT). Radiation therapy (RT) can be particularly disruptive due to weeks of daily treatments. Yet, FT in patients receiving RT is less studied, and the extent to...

Descripción completa

Detalles Bibliográficos
Autores principales: Prasad, Rahul N., Royce, Trevor J., Chino, Fumiko, Jagsi, Reshma, Palmer, Joshua D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126781/
https://www.ncbi.nlm.nih.gov/pubmed/35620674
http://dx.doi.org/10.1016/j.adro.2022.100970
_version_ 1784712204049711104
author Prasad, Rahul N.
Royce, Trevor J.
Chino, Fumiko
Jagsi, Reshma
Palmer, Joshua D.
author_facet Prasad, Rahul N.
Royce, Trevor J.
Chino, Fumiko
Jagsi, Reshma
Palmer, Joshua D.
author_sort Prasad, Rahul N.
collection PubMed
description Prior research, predominately retrospective, has increased awareness that patients with cancer are at elevated risk for financial toxicity (FT). Radiation therapy (RT) can be particularly disruptive due to weeks of daily treatments. Yet, FT in patients receiving RT is less studied, and the extent to which FT has been incorporated as an end point in prospective clinical trials involving RT is unknown. Clinicaltrials.gov was queried to identify all observational or interventional studies from 2001 to 2020 wherein RT was administered for cancer. Studies with primary, secondary, or exploratory FT end points were identified through keyword search. For trials incorporating FT outcomes, pertinent study characteristics were collected. Detailed information regarding FT measures was recorded. Descriptive statistics, including frequency counts and proportions, were performed. The overall rate of inclusion of FT end points was calculated, and rates over 5-year intervals were compared using the χ(2) test (α = 0.05). Overall, 10,550 studies involving RT were identified, of which 88 reported FT end points (0.8%). Included FT end points were typically secondary (78%), with just 15 studies (17%), including primary end points. Notably, only 19 studies (22%) reported a standalone FT end point. The majority measured FT as part of a larger quality of life (QoL) questionnaire. The rate of inclusion of FT end points significantly increased over time from 0.1% from 2001 to 2005 to 1.5% from 2016 to 2020, (P < .0001). FT is a major stressor for patients with cancer, yet even after a relative increase over time, the absolute rate of inclusion of FT end points remains low among RT-based trials. When included, FT outcomes were typically a single question within a QoL assessment not validated as a standalone measure of FT, preventing meaningful study and inference. To characterize and mitigate this burden more accurately, future prospective studies should include FT end points with greater frequency.
format Online
Article
Text
id pubmed-9126781
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91267812022-05-25 Financial Toxicity as an End Point in Prospective Clinical Trials Involving Radiation Therapy Prasad, Rahul N. Royce, Trevor J. Chino, Fumiko Jagsi, Reshma Palmer, Joshua D. Adv Radiat Oncol Brief Opinion Prior research, predominately retrospective, has increased awareness that patients with cancer are at elevated risk for financial toxicity (FT). Radiation therapy (RT) can be particularly disruptive due to weeks of daily treatments. Yet, FT in patients receiving RT is less studied, and the extent to which FT has been incorporated as an end point in prospective clinical trials involving RT is unknown. Clinicaltrials.gov was queried to identify all observational or interventional studies from 2001 to 2020 wherein RT was administered for cancer. Studies with primary, secondary, or exploratory FT end points were identified through keyword search. For trials incorporating FT outcomes, pertinent study characteristics were collected. Detailed information regarding FT measures was recorded. Descriptive statistics, including frequency counts and proportions, were performed. The overall rate of inclusion of FT end points was calculated, and rates over 5-year intervals were compared using the χ(2) test (α = 0.05). Overall, 10,550 studies involving RT were identified, of which 88 reported FT end points (0.8%). Included FT end points were typically secondary (78%), with just 15 studies (17%), including primary end points. Notably, only 19 studies (22%) reported a standalone FT end point. The majority measured FT as part of a larger quality of life (QoL) questionnaire. The rate of inclusion of FT end points significantly increased over time from 0.1% from 2001 to 2005 to 1.5% from 2016 to 2020, (P < .0001). FT is a major stressor for patients with cancer, yet even after a relative increase over time, the absolute rate of inclusion of FT end points remains low among RT-based trials. When included, FT outcomes were typically a single question within a QoL assessment not validated as a standalone measure of FT, preventing meaningful study and inference. To characterize and mitigate this burden more accurately, future prospective studies should include FT end points with greater frequency. Elsevier 2022-04-18 /pmc/articles/PMC9126781/ /pubmed/35620674 http://dx.doi.org/10.1016/j.adro.2022.100970 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Brief Opinion
Prasad, Rahul N.
Royce, Trevor J.
Chino, Fumiko
Jagsi, Reshma
Palmer, Joshua D.
Financial Toxicity as an End Point in Prospective Clinical Trials Involving Radiation Therapy
title Financial Toxicity as an End Point in Prospective Clinical Trials Involving Radiation Therapy
title_full Financial Toxicity as an End Point in Prospective Clinical Trials Involving Radiation Therapy
title_fullStr Financial Toxicity as an End Point in Prospective Clinical Trials Involving Radiation Therapy
title_full_unstemmed Financial Toxicity as an End Point in Prospective Clinical Trials Involving Radiation Therapy
title_short Financial Toxicity as an End Point in Prospective Clinical Trials Involving Radiation Therapy
title_sort financial toxicity as an end point in prospective clinical trials involving radiation therapy
topic Brief Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126781/
https://www.ncbi.nlm.nih.gov/pubmed/35620674
http://dx.doi.org/10.1016/j.adro.2022.100970
work_keys_str_mv AT prasadrahuln financialtoxicityasanendpointinprospectiveclinicaltrialsinvolvingradiationtherapy
AT roycetrevorj financialtoxicityasanendpointinprospectiveclinicaltrialsinvolvingradiationtherapy
AT chinofumiko financialtoxicityasanendpointinprospectiveclinicaltrialsinvolvingradiationtherapy
AT jagsireshma financialtoxicityasanendpointinprospectiveclinicaltrialsinvolvingradiationtherapy
AT palmerjoshuad financialtoxicityasanendpointinprospectiveclinicaltrialsinvolvingradiationtherapy